PML or PML-RARα protein solubility changes, hyper-SUMOylation and degradation in response to As2O3 (i.e., iAsIII) constitute the molecular mechanisms of arsenic-induced treatment of APL [14,25]. This evidence concerns the gene RARA and acute promyelocytic leukemia.